A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide |
| |
Authors: | AKIRA TERANO TETSUO ARAKAWA TOSHIRO SUGIYAMA TOSHIKAZU YOSHIKAWA KEN HARUMA MASAHIRO ASAKA TOORU SHIMOSEGAWA NOBUHIRO SAKAKI HIROMASA ISHII CHOITSU SAKAMOTO SHIN-ICHI TAKAHASHI YOSHIKAZU KINOSHITA TOSHIO FUJIOKA KENZO KOBAYASHI |
| |
Affiliation: | Department of Gastroenterology, Dokkyo University School of Medicine,;Department of Gastroenterology, Osaka City University Graduate Medical School,;Third Department of Internal Medicine, Hokkaido University School of Medicine,;First Department of Internal Medicine, Kyoto Prefectural University of Medicine,;Department of Internal Medicine, Kawasaki Medical School,;Division of Gastroenterology, Tohoku University Graduate School of Medicine,;Department of Internal Medicine, Tokyo Metropolitan Hiroo Hospital,;Department of Internal Medicine, Keio University School of Medicine,;Third Department of Internal Medicine, Nippon Medical School,;Third Department of Internal Medicine, Kyorin University School of Medicine,;Department of Gastroenterology and Hepatology, Shimane University School of Medicine and;Department of General Medicine, Oita University School of Medicine, Japan |
| |
Abstract: | Background and Aim: Controversies remain over the need for antiulcer treatment following 1‐week eradication triple therapy for Helicobacter pylori‐positive peptic ulcers. The usefulness of combination therapy for gastric ulcers in Japanese patients, which consists of H. pylori eradication followed by gastroprotective therapy with rebamipide, was therefore evaluated. Methods: The study was conducted in 52 H. pylori‐positive patients with an endoscopically‐proven open gastric ulcer. All patients received 1‐week triple therapy (lansoprazole, amoxicillin and clarithromycin) followed by 7‐week rebamipide therapy. After completion of the combination therapy, all patients underwent evaluation of ulcer healing by endoscopy, gastric ulcer symptoms and H. pylori eradication by rapid urease test and 13C‐urea breath test. Results: The ulcer healing rates were 85.7% (36/42) at 8 weeks, 83.3% (30/36) in eradicated patients and 100% (6/6) in non‐eradicated patients. The overall gastrointestinal symptom‐free rate improved from 19.0% at baseline to 88.1% at 8 weeks. H. pylori was effectively eradicated in 85.7% (36/42) of patients. Conclusions: The results suggested that the combination therapy for open gastric ulcer was safe, well‐tolerated and effective. However, data from a double‐blind placebo‐controlled study is necessary to confirm these findings. |
| |
Keywords: | gastric ulcer Helicobacter pylori pepsinogen rebamipide ulcer healing |
|
|